Cite
HARVARD Citation
van der Heijde, D. et al. (n.d.). SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years' treatment. Annals of the rheumatic diseases. p. 1027. [Online].